Clinical Trial Update: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes REGN846 given in sequential doses for refractory pruritus in patients with atopic dermatitis (Phase 1/2); the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• REGN846

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Pruritus, Atopic Dermatitis | Phase 1, Phase 2 | Status: TERMINATED